In this section
Rapid analysis of NPM1 and FLT3 by gene fragment analysis is indicated in newly diagnosed AML to aid accurate diagnosis and for therapeutic decision making.
In patients with NPM1 variants, post-treatment analysis by real-time PCR provides an assessment of residual disease burden and can support long term clinical management.